Sensus Healthcare — Third Quarter 2026 Earnings Summary

Financial Performance:

• Revenues were $6.0 million for the quarter ended September 30, 2026, a 13.0% decrease from $6.9 million in the prior-year period.
• Gross profit increased to $3.3 million from $2.7 million in the prior-year period, with gross margin improving to 55% from 39.1%.
• Cost of sales decreased to $2.7 million from $4.2 million in the prior-year period, a 35.7% reduction.
• General and administrative expenses rose to $2.3 million from $1.9 million in the prior-year period, a 21.1% increase.
• Selling and marketing expenses remained flat at $1.5 million compared to the prior-year period.
• Research and development expenses decreased to $1.1 million from $1.8 million in the prior-year period, a 38.9% reduction.
• Net loss was $1.5 million ($0.09 per share), compared to a net loss of $0.9 million ($0.06 per share) in the prior-year period.
• Adjusted EBITDA was a negative $1.5 million, an improvement from negative $2.4 million in the prior-year period.
• Cash, restricted cash, and cash equivalents were $12.9 million as of September 30, 2026, down from $15.2 million as of June 30, 2026.
• Inventories were $18.0 million as of September 30, 2026, compared to $18.5 million as of June 30, 2026.
• The Company had no outstanding borrowings under its revolving line of credit as of September 30, 2026.

Business Segments and Product Lines:

• Unit shipments totaled 26 systems, including eight carried over from the second quarter, compared to 16 systems in the prior-year period.
• Excluding the eight carry-over systems, 18 systems were shipped during the quarter, compared to six shipments to customers other than the Company's historically largest customer in the prior-year period.
• Revenue mix shifted toward lower-priced SRT-100 systems versus higher-priced SRT-100 Vision systems, resulting in a lower average selling price per unit.
• Three systems shipped during the quarter were under the Fair Deal Agreement program and rental arrangements, with revenue recognized over the term of the agreement.
• Initial system purchases were made by two large private equity-backed dermatology groups.
• The Company launched TreatSkinCancer.com, a consumer education resource to increase awareness of skin cancer treatment options.
• International market-development activities advanced across Asia-Pacific, including Australia, New Zealand, China, and Hong Kong.
• Subsequent to the quarter end, the Company placed its 1,000th SRT system.

Management Commentary and Tone:

• CEO Joseph Sardano stated that results reflect progress in building a broader, more diversified customer base and advancing toward sustainable profitability.
• Management noted that dedicated reimbursement codes are now in effect, shifting physician conversations toward bringing SRT into their practices.
• The Company's vision is to make SRT a widely understood and accessible non-invasive treatment option for non-melanoma skin cancer.
• Management emphasized a focus on converting opportunities into sales, increasing utilization, and building a diversified, sustainably profitable business.
• CEO Sardano expressed pride in the milestone of selling the 1,000th SRT system.

Other Key Points:

• The revenue decrease was driven by the absence of sales to a historically large customer and a product mix shift.
• The decrease in research and development expenses was primarily due to reduced lobbying costs and reduced headcount.
• The decrease in general and administrative expenses was offset by higher legal and professional fees.
• Other income of $0.1 million and $0.2 million for the quarters ended September 30, 2026, and 2025, respectively, related primarily to interest income.
• Prepaid inventory was zero as of September 30, 2026, compared to $0.6 million as of June 30, 2026.
• Deferred revenue was $0.785 million (current portion) and $0 (non-current portion) as of September 30, 2026.
• The Company hosted a conference call and webcast for the investment community to discuss results and answer questions.